title: Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
abstract: Despite rapid advances in cancer diagnosis and treatment, pancreatic cancer remains one of the most difficult human malignancies to be treated, with a mortality rate nearly equal to its incidence. Although gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer, gemcitabine-based combination chemotherapy showed either marginal or no improvement in survival. Developments in liposomal delivery systems have facilitated the targeting of specific agents for cancer treatment. Such systems could be developed as platforms for future multi-functional theranostic nanodevices tailor-made for the combined detection of early cancer and functional drug delivery. We systemically review liposome based drug-delivery systems, which can provide improved pharmacokinetics, reduced side effects and potentially increased tumor uptake, for pancreatic cancer therapy. Novel liposomal formulations allowing for higher tumor targeting efficiencies and used in current clinical trials to treat this challenging disease are emphasized.
authors.affiliation: Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China. yffudan98@126.com
authors.forename: Feng
authors.initials: F
authors.lastname: Yang
authors.forename: Chen
authors.initials: C
authors.lastname: Jin
authors.forename: Yongjian
authors.initials: Y
authors.lastname: Jiang
authors.forename: Ji
authors.initials: J
authors.lastname: Li
authors.forename: Yang
authors.initials: Y
authors.lastname: Di
authors.forename: Quanxing
authors.initials: Q
authors.lastname: Ni
authors.forename: Deliang
authors.initials: D
authors.lastname: Fu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes